Advances in allogeneic stem cell transplantation for hemoglobinopathies

Area of Science:

• Hematology
• Transplantation Medicine
• Genetic Blood Disorders

Background:

• Hematopoietic stem cell transplantation (SCT) is the only curative treatment for thalassemia and sickle cell disease.
• Historically, myeloablative conditioning was required, limiting its application.
• Recent advancements include reduced intensity conditioning and expanded stem cell sources.

Purpose of the Study:

• To review the evolution and current status of hematopoietic stem cell transplantation for hemoglobinopathies.
• To highlight improvements in conditioning regimens and stem cell sources.
• To underscore the persistent challenges, particularly human leukocyte antigen (HLA) disparity.

Main Methods:

• Review of current literature on stem cell transplantation for thalassemia and sickle cell disease.
• Analysis of conditioning regimens, including myeloablative and reduced intensity approaches.
• Evaluation of different stem cell sources, such as bone marrow, peripheral blood, and umbilical cord blood.

Main Results:

• Reduced intensity conditioning regimens have broadened the eligibility for SCT in advanced hemoglobinopathies.
• Increased accessibility of stem cell sources, including umbilical cord blood and alternative donors.
• Donor human leukocyte antigen (HLA) disparity remains a critical factor contributing to transplant-related morbidity and mortality.

Conclusions:

• Hematopoietic stem cell transplantation is a viable curative option for hemoglobinopathies.
• Ongoing research focuses on mitigating risks associated with HLA disparity.
• Further optimization of conditioning and donor selection is crucial for improving SCT outcomes.